Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model

被引：0
|
作者：
Tianyun Qiao
Jinbo Zhao
Xiangbing Xin
Yanlu Xiong
Wenwen Guo
Fancheng Meng
Hui Li
Yangbo Feng
Hui Xu
Changhong Shi
Yong Han
机构：
[1] Air Force Medical Center,Department of Thoracic Surgery
[2] Fourth Military Medical University,Department of Thoracic Surgery, Tangdu Hospital
[3] Fourth Military Medical University,Laboratory Animal Center
[4] Fourth Military Medical University,School of Basic Medicine
来源：
Cancer Immunology, Immunotherapy | 2023年 / 72卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1183 / 1183
相关论文
共 50 条
  • [1] Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model
    Qiao, Tianyun
    Zhao, Jinbo
    Xin, Xiangbing
    Xiong, Yanlu
    Guo, Wenwen
    Meng, Fancheng
    Li, Hui
    Feng, Yangbo
    Xu, Hui
    Shi, Changhong
    Han, Yong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (05) : 1169 - 1181
  • [2] Pembrolizumab as adjuvant therapy in non-small-cell lung cancer
    Sorscher, Steven
    LANCET ONCOLOGY, 2022, 23 (12): : E529 - E529
  • [3] Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
    Masuda, Chinami
    Sugimoto, Masamichi
    Wakita, Daiko
    Monnai, Makoto
    Ishimaru, Chisako
    Nakamura, Ryo
    Kinoshita, Mari
    Yorozu, Keigo
    Kurasawa, Mitsue
    Kondoh, Osamu
    Yamamoto, Kaname
    CLINICAL & EXPERIMENTAL METASTASIS, 2020, 37 (01) : 199 - 207
  • [4] Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model
    Chinami Masuda
    Masamichi Sugimoto
    Daiko Wakita
    Makoto Monnai
    Chisako Ishimaru
    Ryo Nakamura
    Mari Kinoshita
    Keigo Yorozu
    Mitsue Kurasawa
    Osamu Kondoh
    Kaname Yamamoto
    Clinical & Experimental Metastasis, 2020, 37 : 199 - 207
  • [5] Bevacizumab Prevents Growth of Established Non-Small Cell Lung Cancer Brain Metastases in Hematogenous Brain Metastasis Model
    Masuda, C.
    Monnai, M.
    Ishimaru, C.
    Nakamura, R.
    Kinoshita, M.
    Yorozu, K.
    Kurasawa, M.
    Sugimoto, M.
    Yamamoto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2117 - S2117
  • [6] Correction: Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer
    Yali Yi
    Jing Cai
    Peng Xu
    Le Xiong
    Zhiqin Lu
    Zhimin Zeng
    Anwen Liu
    Journal of Translational Medicine, 20
  • [7] Local therapy combined with chemotherapy versus chemotherapy for postoperative oligometastatic non-small-cell lung cancer
    Shang, Shuheng
    Wang, Linlin
    Su, Yi
    Li, Butuo
    Guo, Meiying
    Zhu, Zhaofeng
    Sun, Xindong
    Yu, Jinming
    FUTURE ONCOLOGY, 2019, 15 (14) : 1593 - 1603
  • [8] Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
    Reck, Martin
    IMMUNOTHERAPY, 2018, 10 (02) : 93 - 105
  • [9] Prognostic factors for patients with postoperative metastasis from non-small-cell lung cancer
    Bian, Dongliang
    Zhu, Xinsheng
    Jiang, Gening
    Zhang, Peng
    Fei, Ke
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (05): : 8078 - 8085
  • [10] Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer
    Chaft, Jamie E.
    Shyr, Yu
    Sepesi, Boris
    Forde, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 546 - +
12345